Currently Viewing:
Contributor

The Promise of Cancer Immunotherapy: Why Patient Education Is Critical, Part II

Debra Madden is a 2-time cancer survivor who was diagnosed with Hodgkin's lymphoma as a young adult and breast cancer nearly 20 years later, which was thought to be secondary to the radiation she had received for her original cancer treatment. Debra became an active Cancer Research Advocate following her second cancer diagnosis at the age of 42 years. She is currently a member of the ECOG/ACRIN Cancer Research Group and the Patient-Centered Outcomes Research Institute's Advisory Panel on the Assessment of Prevention, Diagnosis, and Treatment Options. She also serves on multiple grant review panels, including the Congressionally Directed Medical Research Program Breast Cancer Research Program. Debra blogs at "Musings of a Cancer Research Advocate", (https://draemadden.wordpress.com/) and you can follow her on Twitter at @AdvocateDebM.
The chart below outlines specific irAEs reported in association with immunotherapy for some patients:4,12

 
System Symptoms
Dermatologic Dermatologic toxicities may result in serious skin reactions, where symptoms may include:
  • Rash with or without itching
  • Skin blistering or peeling
  • Dry mouth
  • Mouth sores (oral mucositis)
  • Loss of skin pigmentation in blotches (vitiligo)
  • In rare cases, severe rashes, such as Stevens-Johnson syndrome 
Gastrointestinal Inflammation of the intestinal lining (colitis) may lead to holes or tears (perforation) in the intestines. Associated symptoms may include:
  • Abdominal pain
  • Diarrhea
  • Increased frequency of bowel movements
  • Dark, tarry stools
  • Blood in the stools
Hepatic Inflammation of the liver (hepatitis) can lead to liver failure. Symptoms and findings associated with hepatitis may include:
  • Elevated liver enzyme levels (AST and ALT)
  • Fever
  • Yellowing of the skin or the whites of the eyes (jaundice)
  • Nausea or vomiting
  • Dark urine
  • Increased bruising
  • Pain on the right side of the stomach
Neurologic Nerve damage (neuropathy) may develop, with symptoms that may include:
  • Tingling or numbness in the hands and feet
  • Abnormal weakness of the arms, legs, or face
  • Various neurologic syndromes have also been reported in association with checkpoint inhibitors, including:
    • Guillain-Barre syndrome, where the immune system attacks part of the peripheral nervous system
    • Myasthenia gravis, an autoimmune neuromuscular disease characterized by fluctuating weakness and fatigue of voluntary muscles
    • Inflammation of  layers of the brain (aseptic meningitis)
Endocrine Endocrine toxicities may primarily affect the pituitary gland (hypophysitis), the thyroid gland (hypothyroidism), and adrenal glands (adrenal insufficiency). Associated symptoms may include:
  • Persistent headaches
  • Fatigue
  • Nausea
  • Vision changes
  • Weight gain
  • Dizziness
  • Fainting
  • Changes in mood and behavior
Adrenal insufficiency, a serious endocrine toxicity potentially associated with the checkpoint inhibitors, is considered an emergency and may cause hypotension, dehydration, and electrolyte imbalances.
 
Renal Symptoms and signs may include:
  • Decreased amount of urine
  • Blood in the urine
  • Swelling of the ankles
  • Loss of appetite
Ocular Symptoms associated with eye inflammation may include:
  • Blurry vision
  • Double vision
  • Eye redness
  • Eye pain
  • Dryness of the eyes
  • Sensitivity of the eyes
Pulmonary Symptoms associated with lung inflammation (pneumonitis) may include:
  • New or worsening cough
  • Shortness of breath
  • Chest pain
 
It is said that Hippocrates wrote, “Natural forces within us are the true healers of disease.” Our hope is that many of the long-sought answers to curing cancer will indeed lie within our own immune systems—and that our next step on this lengthy path will be to find the keys to expanding immunotherapy’s promise to many more of us. In the interim, however, as we strive toward this goal, it’s crucial for our healthcare providers to appropriately inform patients and help to manage expectations.

References
1.       Dizon DS, Krilov L, Cohen E, et al. Clinical cancer advances 2016: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2016;34(9):987-1011. doi:10.1200/JCO.2015.65.8427. 
2.      Feltman R. Why it’s too early to get excited about this “unprecedented” new cancer treatment. The Washington Post website. https://www.washingtonpost.com/news/speaking-of-science/wp/2016/02/16/why-its-too-early-to-get-excited-about-this-unprecedented-new-cancer-treatment/. Published February 16, 2016. Accessed March 21, 2016.
3.      Yuhas A. Cancer researchers claim “extraordinary results” using T-cell therapy. The Guardian website. https://www.theguardian.com/science/2016/feb/15/cancer-extraordinary-results-t-cell-therapy-research-clinical-trials. Published February 15, 2016. Accessed March 21, 2016. 
4.      Green LM. Immunotherapy in cancer care: educating patients about what to expect.  Oncology Nursing News website. http://nursing.onclive.com/publications/oncology-nurse/2015/june-2015/immunotherapy-in-cancer-care-educating-patients-about-what-to-expect#sthash.FeNfHPaO.dpuf. Published June 30, 2015. Accessed March 21, 2016. 
5.      McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockage [published online March 3, 2016]. Science. doi:10.1126/science.aaf1490. 
6.      Begley S. The newest cancer therapies don’t work on everyone. Now, doctors have a clue why. StatNews website. https://www.statnews.com/2016/03/03/cancer-immunotherapy-neoantigens/. Published March 3, 3016.  Accessed March 21, 2016.
7.      Garron E. Time to response to immunotherapy and the concept of pseudoprogression (video transcript). Global Resource for Advancing Cancer Education website.  Published December 15, 2015. Accessed March 22, 2016. http://cancergrace.org/lung/2015/12/15/gcvl_lu_immunotherapy_response_time_pseudoprogression_concept/
8.      Assessing immunotherapy response—why irRC matters: clinical optimization. Institute for Clinical Immuno-Oncology website. http://accc-iclio.org/resources/assessing-immunotherapy-response-why-irrc-matters/. Published June 25, 2015. Accessed March 22, 2016. 
9.      West H. 5 key points on immune checkpoint inhibitors for lung cancer: game changer or just leveling up? Global Resource for Advancing Cancer Education website. Published January 5, 2014. Accessed March 21, 2016.  http://cancergrace.org/lung/2014/01/05/5-key-points-on-immunotherapy-for-lc/
10.    Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.  Cancer Biol Med. 2014;11(4):237-246. doi:10.7497/j.issn.2095-3941.2014.04.002.
11.    Pilones KA, Vanpouille-Box C, Demaria S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol. 2015;25(1):28-33. doi:10.1016/j.semradonc.2014.07.004.
12.   Postow M, Wolchok J. Toxicities associated with checkpoint inhibitor immunotherapy.  UpToDate website. http://www.uptodate.com/contents/toxicities-associated-with-checkpoint-inhibitor-immunotherapy. Literature review current through: Feb 2016.  Updated Jan 6, 2016. Accessed March 22, 2016.  


 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!